Business Context and Reporting Period
Company: MedaSorb Technologies Corporation (operating subsidiary: CytoSorbents, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2009
Status: Development stage company; no commercial revenue generated to date.
Primary Focus: Research, development, and commercialization of the CytoSorb blood purification device, currently targeting regulatory approval (CE Mark) in Europe for the treatment of sepsis.
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 2009 | 9 Months Ended Sep 30, 2008 | 3 Months Ended Sep 30, 2009 | 3 Months Ended Sep 30, 2008 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Total Expenses | $2,459,458 | $2,328,242 | $840,566 | $870,331 |
| Net Loss | $(2,453,154) | $(2,364,478) | $(841,058) | $(862,751) |
| Accumulated Deficit (Inception to Date) | $(78,429,038) | — | — | — |
| Cash and Cash Equivalents (End of Period) | $937,316 | $3,375,041 | $937,316 | $3,375,041 |
| Current Liabilities | $915,835 | $1,027,704 | $915,835 | $1,027,704 |
| Notes Payable | $0 | $50,000 | $0 | $50,000 |
Material Changes vs. Prior Period
- Liquidity Decline: Cash and cash equivalents decreased by approximately $1.81 million (from $2.75M at Dec 31, 2008 to $0.94M at Sep 30, 2009) due to operating losses and investing activities.
- Debt Elimination: The company converted $57,605 of notes payable and accrued interest into Series B Preferred Stock during the quarter, resulting in zero notes payable on the balance sheet.
- Expense Composition: Research and Development expenses increased to $1.60M for the nine-month period (up from $1.38M in the prior year period), while General and Administrative expenses decreased slightly to $0.63M (from $0.68M).
- Equity Activity: Significant non-cash transactions occurred, including the conversion of Series A and Series B Preferred Stock into Common Stock and the issuance of stock-based compensation totaling approximately $179,000.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of $78.4 million and relies on future financing to fund operations.
- Liquidity Runway: Management estimates current cash reserves are sufficient to fund operations into the second quarter of 2010. Additional funding will be required to complete clinical studies and commercialize products.
- Clinical Trial Status: The European clinical study for the CytoSorb device (targeting sepsis) has enrolled 39 patients as of the filing date, with a target of approximately 80 patients. Enrollment has been slower than anticipated, though the number of hospital sites has increased to 12.
- Regulatory Strategy: The company is prioritizing CE Mark approval in Europe over FDA approval in the U.S. to accelerate market entry. Protocol revisions were made to optimize cytokine data collection.
- Legal Proceedings: A trademark dispute with Alkermes, Inc. regarding the name "MedaSorb" was settled in 2008; the operating subsidiary was renamed CytoSorbents, Inc.
- Subsequent Events: In October 2009, the company received $1.1 million from the exercise of Series B warrants. Additional conversions of Preferred Stock to Common Stock occurred in October and November 2009.
Investor Verification Checklist
- Capital Sufficiency: Verify the company's ability to secure financing before the projected Q2 2010 cash runway expires.
- Clinical Enrollment: Monitor the rate of patient enrollment in the European clinical trial to assess the timeline for CE Mark submission.
- Dilution Risk: Review the impact of outstanding warrants (over 31 million shares) and convertible preferred stock on future common share count.
- Regulatory Milestones: Track the outcome of the revised clinical protocol and the subsequent CE Mark application process.
- Revenue Timeline: Confirm that no commercial revenue is expected until regulatory approval is obtained and commercialization begins.